| Campo DC | Valor | Idioma |
|---|
| dc.contributor.author | Bonin, Carla Rezende Barbosa | - |
| dc.contributor.author | Fernandes, Guilherme Côrtes | - |
| dc.contributor.author | Martins, Reinaldo de Menezes | - |
| dc.contributor.author | Camacho, Luiz Antonio Bastos | - |
| dc.contributor.author | Carvalho, Andréa Teixeira | - |
| dc.contributor.author | Mota, Licia Maria Henrique da | - |
| dc.contributor.author | Lima, Sheila Maria Barbosa de | - |
| dc.contributor.author | Campi-Azevedo, Ana Carolina | - |
| dc.contributor.author | Martins Filho, Olindo Assis | - |
| dc.contributor.author | Santos, Rodrigo Weber dos | - |
| dc.contributor.author | Lobosco, Marcelo | - |
| dc.date.accessioned | 2021-08-14T14:17:48Z | - |
| dc.date.available | 2021-08-14T14:17:48Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | BONIN, Carla Rezende Barbosa et al. Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals. BMC Bioinformatics, v. 21, 551, 2020. DOI: https://doi.org/10.1186/s12859-020-03845-3. Disponível em: https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-020-03845-3. Acesso em: 14 maio 2021. | pt_BR |
| dc.identifier.uri | https://repositorio.unb.br/handle/10482/41714 | - |
| dc.language.iso | Inglês | pt_BR |
| dc.publisher | BioMed Central | pt_BR |
| dc.rights | Acesso Aberto | pt_BR |
| dc.title | Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals | pt_BR |
| dc.type | Artigo | pt_BR |
| dc.subject.keyword | Vacinas | pt_BR |
| dc.subject.keyword | Febre amarela | pt_BR |
| dc.subject.keyword | Modelos matemáticos | pt_BR |
| dc.subject.keyword | Sistema imunológico | pt_BR |
| dc.subject.keyword | Equações diferenciais | pt_BR |
| dc.rights.license | (CC BY) - This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | pt_BR |
| dc.identifier.doi | https://doi.org/10.1186/s12859-020-03845-3 | pt_BR |
| dc.description.abstract1 | Background: An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions.
Results: This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature.
Conclusions: Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF. | pt_BR |
| dc.description.unidade | Faculdade de Medicina (FMD) | - |
| Aparece nas coleções: | Artigos publicados em periódicos e afins
|
